Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$1.51M Sell
5,413
-2,446
-31% -$693K 0.09% 160
2025
Q1
$2.45M Buy
7,859
+520
+7% +$154K 0.15% 114
2024
Q4
$1.91M Buy
7,339
+2,175
+42% +$645K 0.12% 127
2024
Q3
$1.66M Buy
5,164
+148
+3% +$48.4K 0.11% 139
2024
Q2
$1.57M Buy
5,016
+320
+7% +$94K 0.11% 135
2024
Q1
$1.34M Buy
4,696
+93
+2% +$27.2K 0.1% 150
2023
Q4
$1.33M Sell
4,603
-91
-2% -$24.8K 0.11% 141
2023
Q3
$1.26M Buy
4,694
+612
+15% +$153K 0.12% 130
2023
Q2
$906K Buy
4,082
+35
+0.9% +$8.12K 0.09% 142
2023
Q1
$978K Buy
4,047
+214
+6% +$52.5K 0.11% 128
2022
Q4
$1.01M Sell
3,833
-459
-11% -$123K 0.12% 125
2022
Q3
$967K Buy
4,292
+697
+19% +$169K 0.12% 122
2022
Q2
$875K Buy
3,595
+227
+7% +$55.6K 0.11% 132
2022
Q1
$814K Buy
3,368
+246
+8% +$56.5K 0.08% 153
2021
Q4
$702K Buy
3,122
+14
+0.5% +$2.96K 0.07% 165
2021
Q3
$661K Sell
3,108
-139
-4% -$32K 0.08% 146
2021
Q2
$791K Sell
3,247
-53
-2% -$13K 0.11% 131
2021
Q1
$821K Sell
3,300
-249
-7% -$59.4K 0.13% 125
2020
Q4
$816K Sell
3,549
-99
-3% -$22.8K 0.14% 117
2020
Q3
$927K Buy
+3,648
New +$904K 0.18% 100

Other funds holding AMGN

Graypoint LLC's AMGN Position: Q2 2025 in Review

Graypoint LLC reduced its Amgen (AMGN) stake by 31% in Q2 2025, selling an estimated $693K and leaving 5,413 shares worth $1.51M. The position accounts for 0.09% of the portfolio, ranked #160.

Graypoint LLC first reported a position in AMGN in Q3 2020 and has held it in 20 quarters since. The position peaked at $2.45M in Q1 2025. 2,851 funds tracked by Wall St. Rank hold AMGN as of Q2 2025.

  • Graypoint LLC held 5,413 shares of Amgen worth $1.51M as of Q2 2025.
  • Graypoint LLC sold 2,446 Amgen shares in Q2 2025, an estimated $693K.
  • Amgen made up 0.09% of Graypoint LLC's portfolio in Q2 2025, its #160 holding.
  • Graypoint LLC first reported a position in Amgen in Q3 2020 and has held it in 20 quarters since.
  • Graypoint LLC's Amgen position peaked at $2.45M in Q1 2025.
  • 2,851 funds tracked by Wall St. Rank held Amgen as of Q2 2025.

Based on Graypoint LLC's 13F filing for Q2 2025, filed 15 Jul 2025.